GPC3/TRGV9 Bispecific antibody (Hengrui)

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameGPC3/TRGV9 Bispecific antibody (Hengrui)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Glypican-3Anti-TRGV9

TargetsGlypican-3T cell receptor gamma variable 9

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesJiangsu Hengrui Pharmaceutical Group Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Hengrui Pharmaceutical Group Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A